Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00489411 · ClinicalTrials.gov registry record · Phase 3
Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
A Phase 3 study of Pain and Unspecified Adult Solid Tumor, Protocol Specific, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 231
- Enrollment target
- 20
- Study locations
NCT00489411 is a Phase 3 study of Pain and Unspecified Adult Solid Tumor, Protocol Specific that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 231 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (24% lower). The trial reports 20 study locations across 1 state.
The verdict
NCT00489411, a Phase 3 study of Pain and Unspecified Adult Solid Tumor, Protocol Specific, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 231 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Duloxetine may lessen peripheral neuropathy caused by chemotherapy. It is not yet known whether duloxetine is more effective than a placebo in treating peripheral neuropathy caused by chemotherapy. PURPOSE: This randomized phase III trial is studying duloxetine to see how well it works compared with a placebo in treating peripheral neuropathy caused by chemotherapy in patients with cancer.
Conditions Studied
Interventions
- OTHER placebo
- DRUG duloxetine hydrochloride
Study Locations (20)
California
- Kaiser Permanente - Deer Valley - Antioch
- Alta Bates Summit Comprehensive Cancer Center - Berkeley
- Peninsula Medical Center - Burlingame
- East Bay Radiation Oncology Center - Castro Valley
- Valley Medical Oncology Consultants - Castro Valley - Castro Valley
- Cancer Care Center at John Muir Health - Concord Campus - Concord
- Kaiser Permanente - Fremont - Fremont
- Valley Medical Oncology - Fremont
- Glendale Memorial Hospital Comprehensive Cancer Center - Glendale
- Kaiser Permanente Medical Center - Hayward - Hayward
- Rebecca and John Moores UCSD Cancer Center - La Jolla
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
- Contra Costa Regional Medical Center - Martinez
- Camino Medical Group - Treatment Center - Mountain View
- El Camino Hospital Cancer Center - Mountain View
- Highland General Hospital - Oakland
- Alta Bates Summit Medical Center - Summit Campus - Oakland
- Bay Area Breast Surgeons, Incorporated - Oakland
- CCOP - Bay Area Tumor Institute - Oakland
- Larry G Strieff MD Medical Corporation - Oakland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 231 participants |
| Start Date | 2008-04 |
| Est. Completion | 2013-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00489411
The ClinicalTrials.gov registry entry for NCT00489411 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 231 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (24% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00489411 reports 20 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00489411 about?
NCT00489411 is a clinical study titled "Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer". RATIONALE: Duloxetine may lessen peripheral neuropathy caused by chemotherapy. It is not yet known whether duloxetine is more effective than a placebo in treating peripheral neuropathy caused by chemotherapy. PURPOSE: This randomized phase III trial is studying duloxetine to see how well it works c...
What is the current status of trial NCT00489411?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 231 participants. The study started on 2008-04. Estimated completion is 2013-03.
What conditions does trial NCT00489411 study?
This clinical trial studies the following conditions: Pain, Unspecified Adult Solid Tumor, Protocol Specific, Peripheral Neuropathy, Neurotoxicity.
What interventions are being tested in trial NCT00489411?
The interventions under investigation include: placebo (OTHER), duloxetine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00489411?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00489411 being conducted?
This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures: A Pragmatic, Randomized Controlled Trial
RECRUITING · Phase 3
-
Opioid-Free Orthopaedics
RECRUITING · Phase 3
-
Suzetrigine in Total Hip Arthroplasty
RECRUITING · Phase 3
-
Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits
RECRUITING · Phase 3
-
Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment
RECRUITING · Phase 3
-
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.